Allergy Therapeutics PLC has recently issued 2,565,167 ordinary shares in satisfaction of the exercise of share options. The new Ordinary Shares rank pari passu with the Company's existing shares. As of 29 December 2023, the Company has 4,766,439,938 Ordinary Shares in issue, with no shares held in treasury, resulting in a total number of voting rights in the Company of 4,766,439,938. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, interested parties can contact Allergy Therapeutics at +44 (0)1903 845 820 or Panmure Gordon at +44 (0)20 7886 2500. Additionally, ICR Consilium can be reached at +44 (0)20 3709 5700 or [email protected].

Allergy Therapeutics is a company focused on the development of allergy vaccines with a strong pipeline of products in various stages of development.